02333nam 2200445z- 450 991026113410332120231214133246.0(CKB)4100000002484751(oapen)https://directory.doabooks.org/handle/20.500.12854/61823(EXLCZ)99410000000248475120202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierVaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New FrontierFrontiers Media SA20171 electronic resource (183 p.)Frontiers Research Topics2-88945-327-8 Invasive fungal diseases have increased many fold over the past 50 years. Current treatment regimens typically require prolonged administration of antifungal medications that can have significant toxicity. Moreover, our present potent antifungal armamentarium fails to eradicate fungal pathogens from certain compromised hosts. Additionally, invasive fungal diseases continue to have unacceptably high mortality rates. A growing body of work has focused on the utility of vaccines and/or immunotherapy as a powerful tool in combating mycoses, either for the active treatment, as an adjuvant, or in the prevention of specific fungal pathogens. Also, it is growing the interest over new drugs development as second choice for treatment when traditional chemotherapy fail. This Research Topic will detail the exciting progress in developing vaccines, immunotherapy and new drugs for fungi.Vaccines, Immunotherapy and New Antifungal Therapy Against FungiVaccines; Immunotherapy and New Antifungal Therapy Against Fungiantifugal drugsvaccinepeptideantibodyvirulencefungiimmunotherapyhumanized antibodymycosiscell biologyCarlos P. Tabordaauth1311259Joshua D. NosanchukauthBOOK9910261134103321Vaccines, Immunotherapy and New Antifungal Therapy Against Fungi: Updates in the New Frontier3030066UNINA